MARKET

BOLT

BOLT

Bolt Biotherapeutics, Inc.
NASDAQ
6.26
-0.04
-0.63%
Opening 10:50 11/11 EST
OPEN
6.38
PREV CLOSE
6.30
HIGH
6.38
LOW
6.18
VOLUME
2.83K
TURNOVER
--
52 WEEK HIGH
7.78
52 WEEK LOW
3.100
MARKET CAP
12.06M
P/E (TTM)
-0.3807
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BOLT last week (1102-1106)?
Weekly Report · 2d ago
Bolt Biotherapeutics Consensus Price Target Increased by 1,400% to $76.50
NASDAQ · 11/02 23:12
Weekly Report: what happened at BOLT last week (1026-1030)?
Weekly Report · 11/02 09:25
Weekly Report: what happened at BOLT last week (1019-1023)?
Weekly Report · 10/26 09:25
Biotech Stocks On Investor Radar - BOLT +66%, LYCA +33%, LUCD, GMAB
NASDAQ · 10/23 19:00
Why Is Penny Stock Bolt Biotherapeutics (BOLT) Up 62% Today?
TipRanks · 10/23 18:19
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 10/23 17:05
Bolt Biotherapeutics Acquires Prana, Secures $120M To Advance PRA-216 Pipeline; Stock Up
NASDAQ · 10/23 16:44
More
About BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in half-life-extended multispecific antibodies designed to deliver therapies. Through the proprietary INSPIRE platform, the Company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for efficacy and extended exposure. Its lead program, PRA-216, is a novel IL-4Ra/TSLP bispecific antibody in Phase II development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase II study planned in eosinophilic esophagitis. In addition to PRA-216, the Company is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need. Its second program is an IL-31 containing bispecific antibody being developed initially for atopic dermatitis. The Company is open to various partnering programs, including BDC-3042: P2-ready Dectin-2 Agonist mA, Preclinical CEA ISAC and Preclinical PD-L1 ISAC.

Webull offers Bolt Biotherapeutics Inc stock information, including NASDAQ: BOLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BOLT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BOLT stock methods without spending real money on the virtual paper trading platform.